The Efficacy And Safety Of Selexipag In Treatment Of Pulmonary Arterial Hypertension:A Meta-analysis

Background:Pulmonary arterial hypertension(PAH)is a kind of disease characterized by increased pulmonary vascular,resulting in right ventricular failure.Selexipag is the first prostacyclin receptor agonist can be given orally.Objective: To evaluate the clinical efficacy and safety of selexipag in the treatment of pulmonary hypertension by Meta analysis.Methods: Computer retrieval database in Chinese(Chinese journal full-text database and Chinese science and technology periodical full text database,ten thousand party journal full digital library)and English databases(Pubmed,the Cochrane library,EMBASE),retrieval time to September 2019 in accord with standard of literature into the article,and uneffective quality evaluation,then use the RevMan5.3 software for Meta-analysis effect value.The outcome indexes were overall mortality and adverse events,6-minute walking test,mean pulmonary artery systolic pressure,cardiac function index,and Pulmonary vascular resistance.Results: A total of 2187 patients with pulmonary hypertension were enrolled in 9 studies.Results show selexipag pulmonary hypertension treatment can obviously improve 6-minute walking test(MD =53.24,95%CI[15.08,91.39],P<0.05),which can effectively improve patient mortality(merger OR a value of 0.70,95%CI[0.55~0.90],P=0.004),can reduce pulmonary vascular resistance(SMD =-2.83,95%CI[-4.43,-1.24],P<0.05),can obviously improve cardiac index(MD = 0.35,95 %CI[0.15,0.57],P<0.001),could effectively reduce the average pulmonary arterial pressure of PAH(MD=-6.24,95%CI[-7.97,-4.52],P<0.05)and the incidence of headache was significant(OR = 3.8,95%CI[3.15,4.59],P<0.05).Conclusion: As a safe drug for pulmonary hypertension,selexipag is effective in improving 6MWD,cardiac index,pulmonary vascular resistance and prognosis.